Base Year
Historical Year
Forecast Year
The Tay-Sachs disease market size was valued at USD 2.3 billion in 2023, driven by the rising advancements in stem cell therapies across the major markets. The market is expected to grow at a CAGR of 5.6% during the forecast period of 2024-2032, with the values likely to rise from USD 2.5 billion in 2024 to USD 3.83 billion by 2032.
Tay-Sachs disease is a rare genetic condition that affects a child’s nerve cells in the brain and spinal cord. It is caused by the absence of an enzyme that helps break down fatty substances (also known as gangliosides). These substances build up to toxic levels and affect the impact the nerve cell functions. Early symptoms of the disease appear at about 3-6 months of age. The muscle development slows down and the child may experience seizures as well.
The Tay-Sachs disease market value is driven by the rising emphasis on mitigating the morbidities associated with the disease, which includes the development of new therapeutics and improving the existing system for improved results. AAV (adeno-associated virus) gene therapy is one of the latest therapies being investigated. It impacted the HexA activity which increased from the baseline and remained stable in patients.
In addition, there has been a significant development in other therapies as well, which includes enzyme replacement therapy, substrate reduction therapy, hematopoietic stem cell transplantation, gene therapies. The market growth is also driven by rising investments and grants for innovative treatment alternatives. The California Institute for Regenerative Medicine (CIRM) has invested a hefty sum of USD 4 million into UC Davis researchers to establish a stem cell gene therapy to treat the condition.
With a key focus on developing a genetic cure for GM2 gangliosidosis (including Tay-Sachs disease), several companies and organizations are collaborating to investigate and develop better therapies. In June 2023, New Hope Research Foundation and Forge Biologics partnered for the cGMP manufacturing to enhance the Foundation's NHR01, a novel gene therapy. Such collaborations are essential to meet the rising Tay-Sachs disease market demand and expected to boost market growth further in the coming years.
Market Breakup by Drug Type
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Early screening during pregnancy is a key method to prevent genetic disorders in children. As a result, pregnancy screenings are considered highly critical nowadays. In the historical period, the condition has been more prevalent in Central and Eastern European Jewish ancestry, therefore, Europe has led the Tay-Sachs disease market share. Having a robust healthcare, along with academic institutions, there have been significant enhancements to decrease the rising burden of the disease.
In North America, the United States is a major market with a heavy focus on disease detection at the pregnancy stage. Organizations such as JScreen have set up campaigns and have been actively encouraging people to undergo testing for genetic diseases. In the case of in-vitro fertilization, preimplantation genetic testing is widely applied.
Asia Pacific is expected to witness exponential Tay-Sachs disease market growth, with increasing medical and research advancements occurring in the region. Mergers and acquisitions between native and international corporations is further fostering the market growth in the region. In addition, foreign investments to put the easy availability of resources to use are also impacting the market positively.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 2.3 billion in 2023, driven by the rising advancements in stem cell therapies across the 7 major markets.
The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032, likely to reach a market value of USD 3.83 billion by 2032.
The market demand is driven by the heavy emphasis on early detection of the condition with the help of genetic testing tools.
The market trend involves increasing collaborations between organizations to find quality therapeutics for the condition. In June 2023, New Hope Research Foundation and Forge Biologics collaborated to manufacture cGMP to enhance the Foundation's NHR01, a novel gene therapy.
Based on types, the market is divided into infantile Tay-Sachs disease, juvenile Tay-Sachs disease, and late-onset Tay-Sachs disease.
Medication, respiratory care, and physical therapy are common treatments available in the market.
Anticonvulsants and antipsychotic medications, among others are the common drug types.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Major end users in the market include hospitals and homecare.
The route of administration can be oral and/or injectable, among others.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Recursion Pharmaceuticals, Inc., IntraBioInc, Johnson & Johnson Services, Axovant Sciences, Inc., Pfizer, Sio Gene Therapies Ltd., F. Hoffmann-La, Roche Ltd., Bayer AG, Bausch Health, and Boehringer Ingelheim International GmbH.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share